RSV vaccine with an immune booster, alone or with pneumococcal vaccine, in COPD
Tests an RSV vaccine's immune effects in people with COPD aged 60 and older.
Key facts
- Who runs it
- Nordsjaellands Hospital
- Where
- Hilleroed, DenmarkSee the site
- Trial code
- Registry title
- COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 60 people, planned
- Started
- 1 Sept 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 8 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 60 or older with COPD who need hospital outpatient care and had a PPV23 vaccine more than one year ago.
- Age
- 60 years or older
- Sex
- Women and men can both join.
- Disease stage
- A COPD diagnosis confirmed by a lung specialist, needing care at the hospital outpatient clinic.
- Earlier treatment
- Must have had the PPV23 vaccine more than one year before joining. Must never have had any PCV or RSV vaccine.
Main reasons for not taking part
- Weakened immune system, for example HIV, cancer chemotherapy or medicines that suppress the immune system
- Any earlier PCV or RSV vaccine
- Acute illness in the past 14 days, including COPD flare-ups and fever
- Any other vaccine in the past four weeks
- Allergy to an ingredient of the trial medicine
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- A confirmed COPD diagnosis by a respiratory medicine specialist requiring attention at the hospital's outpatient clinic
- Age≥60 years
- Previous PPV23 vaccination more than one year before inclusion
- Volunteer agrees to participate in all aspects of the trial and has signed the informed consent
Who cannot take part
- Receipt of any PCV or RSV vaccine at any time
- Acute illness within the previous 14 days (including COPD exacerbations and fever)
- Receipt of any other vaccine within the last four weeks
- Allergens towards one of the ingredients in the trial medication
- Immunocompromised status (primary, or secondary immunodeficiencies e.g., HIV, cancer therapy chemo, any medications that would suppress the immune system)
- Previous illness with Gullain-Barré syndrome
Where in Denmark
- Nordsjaellands HospitalHilleroed, DenmarkNot yet recruiting
About the trial
What the trial wants to find out
This study aims to evaluate the specific and non-specific effects of innate immune activation induced by the AS01-adjuvanted RSV vaccine in individuals at high risk for severe respiratory disease and insufficient vaccine response. Our specific objectives are: 1. To investigate whether the AS01-adjuvanted RSV vaccine induces potent mucosal and systemic innate responses in COPD patients aged ≥ 60 years. 2. To evaluate whether ipsi- and/or contralateral co-administration with PCV20 enhances the vaccine-specific adaptive immune response to pneumococcal antigens. 3. To assess non-specific effects of the AS01-adjuvanted RSV vaccine regarding a) the duration of innate enhancement that affects adaptive responses using a controlled delayed vaccine-coadministration model, b) mucosal protection against viral and bacterial respiratory pathogens, and c) sustained systemic control of viral replication in chronic or latent infections.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients
- Plain-language title
- RSV vaccine with an immune booster, alone or with pneumococcal vaccine, in COPDGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 8 December 2025